Simcyp は、医薬品開発における生理学的薬物動態学（PBPK）の開発と応用を先駆けて推進してきました。From addressing safety issues such as drug-drug-interaction (DDI), to extrapolation of clinical outcomes in untested populations such as pediatric and organ impaired, Simcyp has delivered on its promise of expediting drug development for >25 years. Simcyp PBPK models describe the drug concentration in different organs, behavior across different body tissues, and thus help to inform clinical trial design, first-in-human dosing, formulation design, dose differentiation for special populations, and predictions related to potential DDIs
Simcyp™ サクセスストーリー
